Brazilian Tree Compounds Block SARS-CoV-2 in Lab Tests—But Are They a COVID-19 Cure?
Compounds extracted from the leaves of a Brazilian tree have shown powerful activity against SARS-CoV-2 in laboratory experiments, blocking the virus at several stages of infection. The discovery is scientifically promising, but headlines claiming that a tree extract can “destroy COVID-19” leave out a crucial detail: the research was conducted in cultured cells and computer models, not in human patients.
Published in Scientific Reports in February 2026, the study found that galloylquinic acids from Copaifera lucens interfered with viral entry, replication, protein production, and infectivity. The results could support the development of a future antiviral drug, but animal studies, formulation research, toxicity testing, and clinical trials are still required before anyone can know whether the compounds are safe or effective as a treatment.
The finding is therefore neither a miracle cure nor an insignificant laboratory curiosity. It is an early but compelling example of how biodiversity can provide chemical starting points for medicines against emerging infectious diseases.
What Did Scientists Discover in the Brazilian Tree?
Researchers studied a group of naturally occurring compounds called galloylquinic acids, commonly abbreviated as GQAs.
The compounds were extracted from the leaves of Copaifera lucens Dwyer, a tree endemic to Brazil and found primarily in the Atlantic Forest. The species belongs to the Copaifera genus, whose members have long attracted scientific attention because they produce chemically diverse substances with potential pharmacological properties.
The research team prepared a plant fraction highly enriched in several galloylquinic acid derivatives. Rather than testing ordinary leaves, homemade tea, or crude plant material, the scientists used a controlled laboratory extraction and purification process.
The leaves were dried, powdered, extracted with 70% ethanol, separated into different chemical fractions, concentrated, freeze-dried, and analyzed using high-performance liquid chromatography. The selected fraction contained six major galloylquinic acid derivatives and was prepared at precise concentrations for laboratory experiments.
This distinction is essential.
The study did not demonstrate that eating the leaves, drinking an herbal infusion, or buying an unregulated plant extract could prevent or treat COVID-19. It investigated a chemically characterized fraction under controlled experimental conditions.
Who Conducted the Study?
The study was authored by an international group of researchers from Brazil, Egypt, Spain, and other collaborating institutions.
Professor Jairo Kenupp Bastos of the University of São Paulo’s Ribeirão Preto School of Pharmaceutical Sciences coordinated the research. His group has extensive experience studying the phytochemistry and pharmacology of Copaifera species.
The biological research was jointly led by scientists including Mohamed Abd El-Salam, Lamiaa A. Al-Madboly, and Rasha M. El-Morsi, with additional collaboration from researchers connected to Egyptian universities and institutions. The project also received support from the São Paulo Research Foundation, known as FAPESP.
The article was published as:
El-Morsi, R. M., Al-Madboly, L. A., Bastos, J. K., Aboukhatwa, S. M., Nasr, S. A., Ghareeb, D. A., Ramadan, H. A., Kushkevych, I., and Abd El-Salam, M. A. “Bioactive galloylquinic acids from Copaifera lucens as dual inhibitors of SARS-CoV-2 Spike and RdRp proteins.” Scientific Reports, volume 16, article 4521, published February 2, 2026.
SARS-CoV-2 and COVID-19 Are Not the Same Thing
Before interpreting the findings, it helps to separate two terms that are frequently used as though they mean the same thing.
SARS-CoV-2 is the virus.
COVID-19 is the disease that can develop after infection with that virus.
A chemical compound can directly inactivate viral particles or prevent a virus from multiplying in cells. It cannot literally “destroy COVID-19,” because COVID-19 describes the illness and the effects of infection on the body.
A more scientifically accurate statement is that galloylquinic acids from Copaifera lucens demonstrated antiviral activity against SARS-CoV-2 in laboratory tests.
That wording may sound less dramatic, but it reflects what the researchers actually measured.
How the Brazilian Tree Compounds Attacked the Virus
The study attracted attention because the plant-derived compounds did not appear to act at only one point in the viral life cycle.
They demonstrated several complementary effects:
- Reduced the virus’s ability to attach to and enter cells
- Suppressed viral replication after infection
- Directly reduced the infectivity of viral particles
- Inhibited the viral papain-like protease
- Reduced the accumulation of major viral proteins
- Showed predicted binding to the spike protein and viral polymerase
This broad activity is described as a multitarget or multimodal mechanism.
A multitarget candidate can be especially interesting in antiviral development because the virus may need to overcome several biological obstacles rather than only one. However, the possibility of reduced resistance remains a scientific hypothesis at this stage. The study did not directly conduct long-term resistance experiments or demonstrate protection against multiple modern variants.
Blocking Viral Attachment and Entry
SARS-CoV-2 begins infection by using its spike protein to interact with receptors on susceptible host cells.
The receptor-binding domain of the spike protein plays a central role in recognizing the human ACE2 receptor. Interfering with that interaction could make it harder for the virus to establish infection.
In the study’s viral adsorption experiment, galloylquinic acids reduced early viral entry-related activity by approximately 80% at a concentration of 250 micrograms per milliliter.
However, the researchers included an important qualification.
The adsorption assay was performed at a low temperature that restricts internalization. It captured early binding events but could not prove with certainty that the compounds acted only by directly preventing spike from attaching to ACE2.
The observed effect might also involve another early post-attachment process.
Additional biophysical testing would be needed to demonstrate direct molecular binding between the galloylquinic acids and the spike receptor-binding domain.
Disrupting Viral Replication
After entering a cell, SARS-CoV-2 must copy its RNA genome to produce new viral particles.
One of the essential components of this process is RNA-dependent RNA polymerase, usually shortened to RdRp. This viral enzyme helps create new RNA copies from the original viral template.
The researchers used post-entry experiments to examine whether galloylquinic acids could interfere after cells had already been exposed to the virus.
At 31.25 micrograms per milliliter, the compounds produced 74.4% inhibition in the replication-focused assay. The level rose to approximately 85.6% at 250 micrograms per milliliter.
Computational docking also predicted that one of the prominent compounds, 3,4,5-tri-galloylquinic acid, could bind strongly within a functionally important region of RdRp.
Computer docking cannot prove that the same interaction will occur inside a patient. It is valuable because it helps researchers identify plausible molecular explanations for experimental observations and prioritize compounds for further testing.
Directly Reducing Viral Infectivity
The study also investigated whether the compounds had a direct virucidal effect.
“Virucidal” means capable of reducing or eliminating a virus’s ability to remain infectious outside or before entering a host cell. It does not automatically mean that the substance can safely remove the virus from a human body.
In the experiment, SARS-CoV-2 particles were exposed to the galloylquinic acid fraction before being added to fresh cells.
The treatment produced a concentration-dependent reduction in infectivity, reaching approximately 87.8% inhibition at 250 micrograms per milliliter.
This result suggests that the plant-derived compounds may interact directly with viral particles or structures required for infection.
Researchers would still need to determine precisely which compounds create this effect, how stable they are, and whether useful concentrations could be reached safely in living tissue.
Inhibiting the Papain-Like Protease
SARS-CoV-2 relies on viral enzymes to process proteins and reproduce successfully.
One of these enzymes is papain-like protease, or PLpro. It helps cut viral polyproteins into functional components and can also interfere with cellular immune signaling.
The Copaifera lucens fraction inhibited PLpro in a concentration-dependent manner.
At 100 micrograms per milliliter, the inhibition rate was approximately 36%. At 300 micrograms per milliliter, it reached 63.68%.
This result adds another potential target to the compounds’ antiviral profile.
Rather than interacting exclusively with the spike protein or polymerase, the fraction may interfere with multiple viral systems involved in entry, processing, replication, and infectivity.
Reducing Viral Protein Production
The scientists used Western blot analysis to examine viral proteins in infected cells treated with different concentrations of the plant compounds.
They observed a concentration-dependent reduction in proteins associated with the virus, including bands corresponding to the spike, nucleocapsid, and presumptive envelope proteins.
The host-cell loading control remained stable, suggesting that the reduction was not simply caused by a general loss of all measurable cellular protein.
Lower viral protein production is consistent with interrupted replication.
If the virus cannot efficiently copy its genetic material or process its proteins, it will have greater difficulty assembling infectious descendants.
How Strong Were the Laboratory Results?
Several measurements made the results particularly interesting to antiviral researchers.
The half-maximal inhibitory concentration, or IC50, was calculated at approximately 3.81 micrograms per milliliter. This represents the concentration associated with a 50% reduction in the measured virus-induced effect under the test conditions.
The half-maximal cytotoxic concentration, or CC50, was approximately 387.7 micrograms per milliliter. This represents the concentration associated with a 50% reduction in the viability of the cultured host cells.
Dividing the CC50 by the IC50 produced a selectivity index of approximately 102.
A higher selectivity index can be encouraging because it suggests that antiviral activity appears at concentrations substantially below those that cause major cellular toxicity in that particular test system.
In the plaque reduction experiment, treatment at 200 micrograms per milliliter reduced viral replication by approximately 93%. The response was dose dependent, meaning greater concentrations generally produced greater inhibition.
These numbers justify further investigation, but they should not be interpreted as treatment success rates in people.
A result such as “93% inhibition” describes what happened in a specific cell-culture experiment. It does not mean that a future medicine would be 93% effective at preventing hospitalization, shortening symptoms, eliminating transmission, or preventing death.
Why the Selectivity Index Matters
A compound that kills both the virus and the host cells is not a useful antiviral.
Researchers therefore compare antiviral potency with cytotoxicity. The goal is to find substances that interfere with the virus at concentrations that remain tolerable to healthy cells.
The reported selectivity index of approximately 102 indicates a relatively wide separation between the measured antiviral concentration and the concentration associated with substantial toxicity in Vero E6 cells.
That is a promising early signal.
It is not a complete safety assessment.
Vero E6 cells originate from African green monkey kidney tissue. They are widely used in virology because they support the replication of many viruses, but they cannot reproduce the full complexity of a human body.
A compound might behave differently in human airway cells, liver cells, heart tissue, the digestive system, or the immune system.
It may also be rapidly broken down, poorly absorbed, unable to reach the lungs, or toxic after repeated exposure.
What Does “Multitarget Antiviral” Mean?
Many antiviral medicines are designed to interfere with one especially important viral component.
Remdesivir, for example, acts primarily on viral RNA replication. Molnupiravir promotes copying errors in the viral genome. Other antivirals target viral proteases.
A multitarget compound or mixture may interact with more than one process.
In the Copaifera lucens study, the galloylquinic acid fraction showed evidence of interfering with:
- Early viral attachment or entry
- Intracellular replication
- Viral protease activity
- Viral protein accumulation
- The infectivity of exposed viral particles
This creates an appealing theory: if a virus must overcome several independent effects, resistance could be more difficult to develop.
Viruses can acquire mutations that reduce the effectiveness of a drug aimed at one protein. A compound that acts through several mechanisms might retain partial activity even when one target changes.
However, “might” is the important word.
The study did not repeatedly expose the virus to galloylquinic acids over many generations to test whether resistant lineages emerged. It also did not compare resistance development directly with currently approved antivirals.
The multitarget profile is therefore a reason for further research, not proof that resistance is impossible.
Did the Compounds Control Inflammation?
Some reports about the study have suggested that the galloylquinic acids could also regulate inflammation or the immune response.
Previous research has associated compounds from this chemical group with several biological activities, and researchers have discussed their possible immunomodulatory value.
However, the central Scientific Reports study focused primarily on antiviral activity, viral targets, cell viability, protein expression, and molecular interactions.
It did not conduct a human clinical study showing that the compounds reduce dangerous inflammation in COVID-19 patients.
Any claims about controlling inflammation in infected people must therefore be treated as a proposed additional benefit requiring dedicated investigation.
A compound can produce antiviral activity in cultured cells without providing clinically meaningful anti-inflammatory effects. Conversely, suppressing inflammation too strongly could sometimes interfere with immune defense.
Future studies would need to measure specific inflammatory pathways, cytokines, immune-cell behavior, organ effects, and clinical outcomes before drawing conclusions.
The Most Important Limitation: This Was Not a Human Trial
The strongest reason for caution is also the simplest.
No people received the compounds.
The antiviral experiments were performed in Vero E6 cell cultures using the hCoV-19/Egypt/NRC-03/2020 SARS-CoV-2 strain. Computer modeling was then used to predict interactions with selected viral proteins.
The study did not establish:
- A safe dose for humans
- An effective method of administration
- Absorption into the bloodstream
- Distribution to infected tissues
- Metabolism by the liver
- Elimination through the kidneys
- Safety during pregnancy
- Interactions with other medicines
- Effectiveness against currently circulating variants
- Reduction in symptoms, hospitalization, transmission, or mortality
These are not minor technical details. They determine whether a promising molecule can become a useful medicine.
Many compounds inhibit viruses in cell cultures but fail during later development because they are toxic, unstable, poorly absorbed, or ineffective in animals and humans.
Imrul
The Study Tested Only One SARS-CoV-2 Strain
The virus used in the experiments came from 2020.
The authors explicitly acknowledged that their findings may not apply equally to newer variants, including Omicron lineages and their descendants. Mutations in the spike protein and other viral proteins can alter cellular entry, immune evasion, and drug susceptibility.
The compounds’ interaction with RdRp and PLpro may offer advantages because these enzymes can be more conserved than some exposed areas of the spike protein.
Nevertheless, this does not guarantee broad effectiveness.
Researchers must repeat the experiments using multiple contemporary variants. They must also determine whether the active compounds maintain potency when viral proteins acquire relevant mutations.
Until those experiments are completed, statements claiming protection against current and future strains are speculative.
Does This Discovery Prove Nature Is Our Best Defense Against Pandemics?
Nature is one of humanity’s most valuable sources of medicinal chemistry, but calling it our single “best defense” oversimplifies pandemic preparedness.
Effective defense against infectious disease requires several connected systems:
- Disease surveillance
- Transparent reporting
- Rapid diagnostic testing
- Vaccination
- Antiviral and supportive treatment
- Public-health communication
- Hospital preparedness
- Infection-control measures
- Genomic monitoring
- International scientific cooperation
- Protection of ecosystems and biological resources
Natural products contribute to this system by providing chemically diverse molecules that scientists can study, modify, and potentially develop into medicines.
They do not replace vaccines, clinical medicine, epidemiology, sanitation, ventilation, or public-health infrastructure.
The lesson from Copaifera lucens is not that unprocessed natural remedies are automatically superior to modern medicine.
The lesson is that modern medicine can benefit enormously from carefully studying nature.
Why Biodiversity Matters for Drug Discovery
Plants, fungi, bacteria, and marine organisms produce molecules that help them survive competition, infection, predation, environmental stress, and physical injury.
Those molecules can interact with biological systems in ways that become useful to medicine.
Natural compounds have contributed to the development of treatments for cancer, malaria, bacterial infections, pain, cardiovascular disease, immune disorders, and many other conditions.
Drug discovery from biodiversity is not simply a matter of collecting a plant and using it directly.
The process usually involves:
- Identifying a species or ecological source
- Extracting and separating chemical fractions
- Characterizing individual molecules
- Testing biological activity
- Studying toxicity and mechanism
- Improving potency or stability
- Developing a reproducible formulation
- Conducting animal studies
- Completing phased clinical trials
- Obtaining regulatory approval
A forest can therefore be viewed as a vast chemical library.
When species disappear before they are documented, their potentially useful molecules may disappear with them.
Brazil’s Extraordinary Biological Wealth
Brazil is recognized as the world’s most biologically diverse country.
The Brazilian Ministry of the Environment reports approximately 44,914 known species of flora, more than 124,000 known animal species, and more than 8,000 species of fungi. It estimates that Brazil contains around 15% of the world’s total species across terrestrial and aquatic environments.
This is more accurate than the frequently repeated claim that Brazil contains nearly one-quarter of all the world’s plant species.
Older estimates placed the percentage higher, but modern national inventories provide a more carefully documented picture. The precise total will continue changing as scientists describe new species and revise classifications.
Brazil’s biodiversity is distributed across several major environments, including the Amazon, Cerrado, Atlantic Forest, Caatinga, Pantanal, Pampa, and extensive coastal and marine ecosystems.
Each biome contains species adapted to different ecological conditions and therefore potentially producing different groups of biologically active chemicals.
Why the Atlantic Forest Is So Important
Copaifera lucens is primarily associated with Brazil’s Atlantic Forest, one of the country’s two internationally recognized biodiversity hotspots alongside the Cerrado.
A biodiversity hotspot contains exceptional concentrations of unique species while also experiencing severe habitat loss and ecological pressure.
The Atlantic Forest once stretched across a vast portion of Brazil’s eastern region. Today, much of its remaining vegetation is fragmented into isolated areas surrounded by cities, roads, farms, industry, and other altered landscapes.
Habitat fragmentation can reduce genetic diversity, separate wildlife populations, disrupt pollination, alter water cycles, increase vulnerability to fire, and make species more difficult to study or protect.
The loss of a forest species is not only an ecological tragedy.
It can also represent the loss of chemical structures, genetic information, traditional knowledge, and research opportunities that humanity never had the chance to understand.
Conservation and Medical Research Must Work Together
A discovery involving a forest species can create demand for biological material.
Without responsible planning, that attention could encourage overharvesting or unregulated commercial exploitation.
Future development of galloylquinic acids should therefore consider sustainability from the beginning.
Researchers and manufacturers would need to examine:
- Whether leaves can be harvested without harming trees
- How slowly the species grows and regenerates
- Whether compounds can be synthesized in laboratories
- Whether cultivated sources can replace wild collection
- How genetic resources are accessed legally
- How benefits are shared with Brazil
- Whether local or traditional knowledge contributed to discovery
- How harvesting could affect the surrounding ecosystem
The goal should not be to protect human health by damaging the biological resource that made the discovery possible.
A successful medicine derived from biodiversity should strengthen the case for conservation, scientific cooperation, lawful access, and equitable benefit-sharing.
Could Galloylquinic Acids Become a COVID-19 Medicine?
Yes, they could become the foundation for a future medicine.
That is scientifically plausible based on the study.
It is not yet known whether they will.
The next stage would typically involve separating and testing individual galloylquinic acid derivatives rather than relying only on an enriched mixture.
Researchers would want to identify which molecule produces the strongest antiviral effect, whether several compounds work together, and whether the activity can be improved through chemical modification.
Further experiments should include:
Human Respiratory Cell Testing
The compounds should be tested in human airway and lung-cell models that more closely represent the tissues affected by respiratory infection.
Advanced organoid or air-liquid interface models could provide information that conventional kidney-derived cell lines cannot.
Testing Against Current Variants
Researchers need to evaluate activity against multiple recent SARS-CoV-2 lineages.
This would show whether the multitarget mechanism provides meaningful breadth or whether potency changes significantly as the virus evolves.
Animal Studies
Appropriate animal models could help determine absorption, tissue distribution, metabolism, toxicity, dosing, and therapeutic effects in a complete living system.
Formulation Development
Scientists must determine how the active molecules could be delivered.
Possible routes might include oral, inhaled, injectable, or localized formulations, but each would create different challenges related to stability and bioavailability.
Clinical Trials
Only carefully controlled human studies can determine whether a candidate treatment is safe and improves meaningful health outcomes.
Trials would need to assess dosage, side effects, symptom duration, viral clearance, hospitalization, complications, and interactions with existing treatments.
Why People Should Not Self-Medicate With Copaifera Leaves
The publication does not justify collecting, buying, boiling, inhaling, or consuming Copaifera lucens leaves.
The laboratory fraction was produced through a multistage extraction and separation process. Researchers then measured concentrations precisely and tested them under controlled conditions.
A homemade preparation could contain an unknown mixture of compounds at unpredictable strengths.
It could also be contaminated, incorrectly identified, chemically unstable, or harmful to the liver, kidneys, digestive system, or other organs.
Natural does not automatically mean safe.
Many of nature’s most powerful substances are toxic. Safety depends on the molecule, dose, formulation, route of administration, duration of exposure, and characteristics of the person using it.
People with COVID-19 should rely on qualified healthcare guidance and approved prevention or treatment options appropriate to their health status and local medical recommendations.
The Real Significance of the Discovery
The most responsible interpretation of the research lies between hype and dismissal.
It is incorrect to say that scientists have already discovered a tree extract that cures COVID-19.
It is also incorrect to suggest that laboratory findings have no value until a finished drug exists.
Early-stage research is how drug development begins.
This study has identified a chemically interesting plant fraction with:
- Strong antiviral activity in cultured cells
- A favorable selectivity index in the tested cell line
- Effects at several stages of viral infection
- Predicted interactions with important viral proteins
- A plausible path toward additional preclinical research
Those findings make galloylquinic acids legitimate candidates for further investigation.
Whether they become a medicine will depend on what happens during the much more difficult stages ahead.
Frequently Asked Questions
Can Copaifera lucens cure COVID-19?
No cure has been demonstrated. Galloylquinic acids extracted from Copaifera lucens inhibited SARS-CoV-2 in cultured cells and showed promising computer-predicted interactions with viral proteins. They have not yet been proven safe or effective in animals or humans.
Did the Brazilian tree extract destroy the coronavirus?
The compounds substantially reduced SARS-CoV-2 infectivity and replication under laboratory conditions. Describing this as “destroying the coronavirus” is an oversimplification because the result has not been reproduced as a treatment inside the human body.
What is Copaifera lucens?
Copaifera lucens is a tree endemic to Brazil and primarily associated with the Atlantic Forest. Its leaves contain galloylquinic acid derivatives that are being investigated for potential pharmacological activity.
What are galloylquinic acids?
Galloylquinic acids are plant-derived polyphenolic compounds formed from quinic acid structures carrying one or more galloyl groups. Researchers study them because some derivatives demonstrate antiviral, antifungal, antioxidant, or other biological activities in experimental systems.
How effective were the compounds in the study?
The enriched galloylquinic acid fraction achieved approximately 93% inhibition in a plaque reduction assay at 200 micrograms per milliliter. Other experiments found effects on viral adsorption, post-entry replication, and direct infectivity. These percentages apply only to the study’s laboratory conditions.
What was the IC50 of the Copaifera compounds?
The reported IC50 was approximately 3.81 micrograms per milliliter in the tested Vero E6 cell system. The CC50 was approximately 387.7 micrograms per milliliter, producing a selectivity index of around 102.
What does a selectivity index of 102 mean?
It means the concentration associated with major cellular toxicity was approximately 102 times higher than the concentration associated with 50% antiviral activity in that particular laboratory test. It is encouraging but does not establish safety in humans.
How did the compounds interfere with SARS-CoV-2?
The experiments indicated interference with early viral adsorption, intracellular replication, viral protein production, PLpro activity, and the infectivity of viral particles. Computational modeling also predicted binding to the spike receptor-binding domain and RNA-dependent RNA polymerase.
Could a multitarget antiviral prevent drug resistance?
A multitarget mechanism may make resistance more difficult because the virus must adapt to several effects. However, this study did not directly prove that SARS-CoV-2 cannot develop resistance to galloylquinic acids.
Did the study test Omicron or recent variants?
No. The researchers tested the hCoV-19/Egypt/NRC-03/2020 strain. They acknowledged that the findings might not fully extend to Omicron and newer lineages without further experiments.
Was the research performed on humans?
No. The antiviral experiments used Vero E6 cells, which originate from African green monkey kidney tissue. No human participants received the compounds.
Can people drink Copaifera lucens leaf tea for COVID-19?
The study provides no evidence that leaf tea is safe or effective. The researchers used a carefully prepared and chemically characterized fraction, not a homemade infusion. Self-medication could be ineffective or harmful.
Is the compound an approved antiviral drug?
No. Galloylquinic acids from Copaifera lucens are experimental antiviral candidates. They have not completed animal testing, human clinical trials, regulatory review, or medicine approval.
What testing must happen next?
Researchers need to test individual compounds in human respiratory cells, current viral variants, animal models, toxicity studies, pharmacokinetic studies, formulation experiments, and phased clinical trials.
Why is the discovery important if it is not yet a medicine?
It identifies a new natural chemical scaffold with several experimentally observed antiviral effects. Such discoveries can provide the starting point for developing optimized drugs, even when the original plant fraction is never used directly as a treatment.
Does Brazil contain one-quarter of the world’s plant species?
Current official Brazilian data reports nearly 45,000 known flora species and estimates that Brazil contains around 15% of the world’s total species across terrestrial and aquatic environments. Claims that nearly one-quarter of all plant species are located in Brazil depend on older estimates and should be used cautiously.
Why does protecting the Atlantic Forest matter for medicine?
The Atlantic Forest contains exceptional biological and genetic diversity, including species that produce chemically unique substances. Habitat destruction can eliminate species before scientists have documented their possible medical, ecological, or technological value.
Does this discovery prove that natural medicine is better than modern medicine?
No. The research demonstrates modern pharmacology using compounds obtained from nature. Laboratory extraction, chemical characterization, virology, computational modeling, toxicology, clinical trials, and regulatory science are all necessary to turn a natural molecule into a reliable medicine.
What is the most accurate conclusion from the study?
Galloylquinic acids extracted from Copaifera lucens showed strong, multitarget antiviral activity against one SARS-CoV-2 strain in laboratory cell experiments. The findings justify further drug-development research but do not establish a COVID-19 cure or an approved treatment.
